Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer's Disease Dementia.

ABSTRACT:

Background

LY3202626 is a small molecule inhibitor of β-site amyloid precursor protein cleaving enzyme (BACE)1 shown to reduce amyloid-β (Aβ)_1-40 and Aβ_1-42 concentrations in plasma and cerebrospinal fluid developed for the treatment of Alzheimer's disease (AD).

Objective

To assess the change from baseline in flortaucipir positron emission tomography (PET) after treatment with LY3202626 compared with placebo in patients with mild AD dementia.

Methods

Patients received daily 3 mg or 12 mg doses of LY3202626 or placebo for 52 weeks. The primary outcome was assessment of cerebral neurofibrillary tangle load by flortaucipir PET. The study was terminated early following an interim analysis due to a low probability of identifying a statistically signif

SUBMITTER: Lo AC 

PROVIDER: S-EPMC8150257 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature